Prima boosted by Cancer Vac trial results
15 July, 2003 by Melissa TrudingerPrima BioMed subsidiary Cancer Vac has announced positive results from the Phase Ib clinical trial of its cancer vaccine immunotherapy.
Capital raising buys time for Alchemia
15 July, 2003 by Pete YoungBrisbane firm Alchemia has capped a lengthy hunt for additional investment by securing $2.75 million in fresh funding, according to CEO Tracie Ramsdale.
Peptech patent approved
15 July, 2003 by Jeremy TorrPeptech's application for a patent on antibodies or antibody fragments that bind to a specific tumour necrosis factor (TNF) has been given the green light by US patent authorities.
Agenix locates DVT clot in clinical trials
11 July, 2003 by Jeremy TorrThrombosis diagnostic specialist Agenix has successfully detected a deep vein thrombosis (DVT) clot in the leg of a patient during Phase Ib clinical trials.
ABI joins call for Aussie roo genome
10 July, 2003 by Iain ScottSequencing instrument company Applied Biosystems has joined the call for a marsupial genome project to be conducted in Australia rather than the US.
Scientists 'terrified' by HK bird flu: Doherty
10 July, 2003 by Graeme O'NeillThe risk of a SARS pandemic sweeping the world appears to be over, to the great relief of international health authorities who have been awaiting another pandemic of the magnitude of the Spanish 'flu pandemic of 1918-19, which killed an estimated 20 million people on six continents.
Botstein awarded Gruber prize
10 July, 2003 by Iain ScottDr David Botstein, of the Lewis-Sigler Institute for Integrative Genomics at Princeton University, was yesterday awarded the prestigious 2003 Peter Gruber Genetics prize.
Research exposes fire ant's Achilles heel
09 July, 2003 by Graeme O'NeillAcross large areas of the southern United States, the most social primate on Planet Earth has come into painful conflict with one of the world's most unlovable social insects - the South American fire ant, Solenopsis victor.
AAV shows promise as mutation repair vector
09 July, 2003 by Melissa TrudingerAdeno-associated virus (AAV) shows promise as a gene-targeting vector for repair of mutations, particularly in cell populations that can be treated ex vivo and reinfused back into the host, according to David Russell, a professor at the University of Washington.
EQiTX granted US patent
09 July, 2003 by Jeremy TorrWA biotech EQiTX has been granted a US patent on its Gingerol pain and inflammation compound.
Mayne forced to re-recall
09 July, 2003 by Jeremy TorrComplementary medicine giant Mayne Health has been caught out in the warehouse department, with some 650 bottles of TGA-banned and recalled products being accidentally delivered to retailers across Australia.
Amgen submits psoriasis drug for marketing review
09 July, 2003 by Deena BeasleyAmgen, the world's No. 1 biotechnology company, said it has asked US regulators to approve the sale of its rheumatoid arthritis drug, Enbrel, to treat the skin disorder psoriasis.
Amrad MD resigns
08 July, 2003 by Melissa TrudingerSandra Webb has resigned as managing director of Amrad to pursue other interests.
GTG boss welcomes 'healthy debate'
08 July, 2003 by Jeremy TorrComments by genomics pioneer Francis Collins that Australian company Genetic Technologies' patents over non-coding DNA were of "questionable appropriateness" have spurred not so much a rebuttal, but more of a philosophical argument from the company's CEO.
Science losing in patent race: Sulston
08 July, 2003 by Graeme O'NeillThe huge trend towards "competitive greed" is having serious consequences for science and innovation internationally, according to eminent British geneticist Sir John Sulston.
